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Abstract
Background: Many people living with chronic HBV infection remain undiagnosed until later stages of disease.
Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral
hepatitis as a public health threat by 2030. However, achieving these ambitious targets is dependent on finding
effective and cost-effective methods of scale up strategies. The aim of this study was to undertake a narrative
review of the literature on economic evaluations of testing and treatment for HBV infection, to help inform the
development of the 2017 WHO Hepatitis Testing Guidelines.
Methods: We undertook a focussed literature review for economic evaluations on testing for HBV accompanied by
antiviral treatment. The search was carried out in Pubmed and included only articles published after 2000 and written
in English. We narratively synthesise the results and discuss the key drivers of cost-effectiveness and their applicability
to low and middle-income countries (LMICs).
Results: Nine published studies were included in this review, only one of which was performed in a low or middle-
income setting in West Africa. Eight studies were performed in high-income settings, seven among high risk groups
and one among the general population. The studies were heterogeneous in many respects including the population
and testing strategy under consideration, model structure and baselines parameters, willingness to pay thresholds and
outcome measures used. However, most studies found HBV testing and treatment to be cost-effective, even at low
HBsAg prevalence levels.
Conclusions: Currently economic evaluations of HBV testing and treatment strategies in LMICs is lacking, therefore
limiting the ability to provide formal recommendations on the basis of cost-effectiveness alone. Further implementation
research is needed in order to help guide national policy planning.
Background
Hepatitis B Virus (HBV) infection is highly prevalent
worldwide, with a disproportionately high burden in low
and middle-income countries (LMICs) [1]. There is
mounting evidence regarding the efficacy of antiviral
therapy in the reduction of disease progression to
cirrhosis and hepatocellular carcinoma (HCC). However,
this impact is not fully translated into practise as many
people still remain unaware of their infection status, in
both high-income countries (HIC) [2–4] and in LMICs
[5]. Wilson and Jungner criteria have been used to assess
whether a disease should screened [6]. However, despite
fulfilling most of these criteria [5], testing for HBV is
not performed systematically. The reasons surrounding
this are likely to be multifactorial, including, lack of
awareness at all levels, lack of clear guidelines, compet-
ing healthcare priorities, limited healthcare budgets and
political will. This leads to many people remaining
undiagnosed until later stages of the disease, when prog-
nosis is poor. Furthermore, even if diagnosed, access to
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appropriate antiviral therapy and ongoing clinical man-
agement is lacking.
Recognising that health care budgets are limited, eco-
nomic evaluations are becoming an increasingly important
tool in informing public health policy [7]. The cost-
effectiveness of infant vaccination has already been estab-
lished in many settings [8], antiviral treatments for HBV
have been found to be cost-effective in many high-income
and upper middle-income settings [9] and studies have
evaluated the cost-effectiveness of various prevention of
mother-to-child transmission (PMTCT) interventions for
HBV; birth dose vaccination [10], birth dose vaccination
combined with HBV immunoglobulin [11–13] and peri-
partum antiviral therapy [14, 15]. Demonstrating that test-
ing in combination with treatment is cost-effective would
provide further support for increasing testing in LMICs
where economic resources are limited.
This study aimed to provide a narrative review of
existing studies on economic evaluation of testing
accompanied by treatment for HBV infection, to help
inform the first global guidelines on viral hepatitis test-
ing from the World Health Organization (WHO) [16]. It
aims to summarise the evidence of the cost-effectiveness
of testing and treatment for HBV infection, identify the
key drivers of cost-effectiveness and determine how
existing literature can inform optimal testing approaches
that are applicable to LMICs.
Methods
The literature was searched to identify relevant published
studies on economic evaluations of HBV testing ap-
proaches and treatment. This study does not represent a
full systematic review as there had been two previously
published systematic reviews by Hahne et al. in 2011 [17]
and Gueue et al. in 2015 [18], both looking at cost-
effectiveness of screening studies in HBV and Hepatitis C
Virus (HCV) infections. However, those two previous re-
views concentrate on results and methodological strengths
of the included studies. The aim of this study is to update
and summarise the existing reviews, and draw overall con-
clusions about key drivers of cost-effectiveness, which
would be most useful for LMIC settings. Although the
burden of HBV is concentrated in LMICs, it was envis-
aged that there would be a lack of relevant literature in
these countries, so existing studies from HICs are in-
cluded and the results summarised below.
Inclusion criteria
Studies for inclusion in this review were selected accord-
ing to the following PICO framework. Population: General
adult population or target populations; Intervention: Test-
ing for chronic HBV infection accompanied by treatment
(not testing prior to vaccination); Comparator: Status quo,
no testing or alternative testing strategies; Outcome:
Studies reporting both costs and benefits; and Study Type:
Economic Evaluations (including CEAs or CBAs).
Exclusion criteria
Studies prior to 2000 were excluded, as older studies
were mainly studying cost-effectiveness of pre-
vaccination testing, rather than testing for consideration
of antiviral therapy. Furthermore, Geue et al., reported
the low methodological standards of cost-effectiveness
analyses in older studies. Non-English language articles
were excluded. Studies that considered testing in blood
banks, among pregnant women or healthcare workers
were excluded, unless the study reported further linkage
into care and treatment for the screened person.
Economic evaluations which included testing for im-
munity prior to vaccination were excluded, unless the
analysis also considered HBsAg testing and subsequent
antiviral therapy for persons tested positive. Studies
looking at testing for HBV prior to chemotherapy were
also excluded, as this was only likely to be relevant to
higher income settings and would only concern a small
sub-set of the populations in LMIC. Finally, studies look-
ing at co-infection with HIV and comparing diagnostic
methods were also excluded.
Search strategy
The bibliography of the two previous systematic reviews
on the cost-effectiveness of HBV screening by Hahné et
al. [17] and Gueue et al. [18] were searched and studies
which met our inclusion criteria were included in our
analysis. Hahne and Gueue searches were performed up
to 2011 and 2012, respectively. An updated focussed
search using PubMed was performed to retrieve any fur-
ther relevant articles on economic evaluation of HBV
testing and treatment. PubMed was searched for articles
published between January 2000 and September 2016,
with terms incorporating ‘Hepatitis B’, ‘HBV’, or ‘chronic
hepatitis B’ and ‘Cost*’ or ‘Economic’ and ‘Screen*’, ‘Test*’
or ‘Diagn*’, in the title only. We did not search any data-
bases other than Pubmed, nor did we search the grey
literature.
Following completion of the search, relevant data was
extracted using a template, which included author, year of
study, country, population/setting, comparator strategies,
method of economic evaluation, baseline parameters
modelled (including HBsAg prevalence and cascade of
care indicators) and result. The quality of each study was
assessed against the Consolidated Health Economic Evalu-
ation Reporting Standards (CHEERS) checklist [19].
Terminology
The term testing rather than screening is used in the
WHO testing guidelines, although we use both terms
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interchangeably in this manuscript. We define other
commonly used terms in this manuscript as follows:-.
Cost effective: An intervention is thought to be cost-
effective when the ICER is below a given willingness-to-
pay threshold (WTP). However, WTP thresholds vary
between settings and are increasingly debated, particu-
larly in LMICs [20]. A full discussion of the use of WTP
thresholds is out of the scope of this current manuscript.
Therefore, for the purposes of this review we used the
authors’ own interpretation of cost-effectiveness and the
threshold that they referred to in their respective manu-
script to define a cost-effective intervention.
High-risk groups: For the purposes of testing for chronic
HBV infection in LMIC, the categorisation of populations
into ‘high-risk’ groups is not always helpful or informative
in guiding policy. Currently, in many LMICs, the adult
general population prevalence (unvaccinated) falls into the
intermediate to high endemicity categories [21]. Further-
more, within countries, Hepatitis B surface antigen
(HBsAg) prevalence is more homogenous within the
population, than is the case with HCV infection. In this
review, we mainly use the term ‘high-risk’ groups when
referring to specific populations examined in studies from
HIC settings (eg migrants, refugees). In the guidelines
[16], high risk groups are those with a high risk of acquisi-
tion because of risk behaviours or exposures (to include
PWIDs, MSM, HIV-infected persons).
Classification of different testing approaches: Viral
hepatitis testing can be delivered to different populations
and in different settings as part of general population
testing, and/or a focused testing approach in most af-
fected or high-risk populations, delivered through either
health facility- based or community-based testing.
General population testing: This approach refers to
routine testing throughout the entire population without
attempting to identify high-risk behaviours or character-
istics. It means that all members of the population
should have potential access to the testing services. This
can include community outreach testing and healthcare
facility based testing.
Focussed or targeted testing: In the guidelines, a fo-
cussed testing approach refers to testing of specific pop-
ulations who are most affected by HBV infection, either
because they are part of a population with high HBV
seroprevalence (such as some migrant populations and
some indigenous populations), or have a high risk of ac-
quisition because of risk behaviours and/or exposures.
Results
Search results
The Pubmed search retrieved 38 studies, many of which
overlapped with the bibliographies of the existing reviews.
After title and abstract review, finally nine published
studies met inclusion criteria and are discussed in further
detail in this manuscript (Table 1).
Summary of main literature
The majority of existing published economic evaluations
of testing and treatment for HBV have been performed
in HICs where the general population prevalence is low.
Only one study was performed in a LIC setting [22].
Two studies evaluated HBV testing in the general popu-
lation [23] and seven studies in ‘high-risk’ groups in HIC
settings (all but one looked at testing in migrant or refu-
gee populations) [24–30]. The studies used different
methods of testing the ‘high risk groups’ including, in
the clinical setting, [27, 26] community outreach
methods [26] and overseas screening [30]. Eight out of 9
studies were cost-effectiveness analyses using various
outcome measures including cost per QALY gained, cost
per DALY averted and cost per case screened. Only one
study was a cost-benefit analysis. All studies used static
cohort models. Most models were simulated using hypo-
thetical cohorts and only 2 used actual screening data to
populate the model. The studies of ANC testing did not
consider antiviral therapy to the mother and only looked
at the benefit of testing in order to guide vaccination
strategies to reduce mother-to-child transmission, and
were therefore excluded in this review.
General population level testing
The studies looking at the cost-effectiveness of offering
testing and treatment to the general population were
from the USA [23] and The Gambia [5].
Eckman et al., [23] examined the cost-effectiveness of
HBsAg testing of asymptomatic outpatients in a primary
care setting in USA to review the US guidelines on
screening populations with a prevalence above 2%. They
used a hypothetical cohort (35 year old male) living in a
region with a prevalence of 2%. Screening was then
followed by treatment with one of four regimens and
compared to a no screening strategy. Screening and
treatment with oral antiviral therapy was found to be
cost-effective with an incremental cost effectiveness ratio
(ICER) of $29,230/QALY (USD 2008). The ICER
remained below their reported willingness-to-pay (WTP)
threshold of $50,000/QALY gained, even down to a
population prevalence of 0.3%. Limitations of this study
include an unrealistic assumed 100% adherence to treat-
ment. Furthermore, the screening costs only included
the cost of a clinic visit and HBsAg testing and no sensi-
tivity analysis was reported on the cost parameters.
The study by Nayagam et al. [22] used primary cost
and effectiveness data from the Prevention of Liver
Fibrosis and cancer in Africa (PROLIFICA) study [5] a
large-scale intervention programme in The Gambia to
determine the cost-effectiveness of adult community-
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based screening and treatment for HBV infection. The
baseline HBsAg prevalence was 8.8%, uptake of screen-
ing 68.9%, linkage to care 81.3% and adherence to anti-
viral therapy 80.9%. Annual drug cost was $48, which is
the generic price of tenofovir available to HIV pro-
grammes. Compared to status quo, the screen and treat
strategy was found to have an ICER of $540 per DALY
(USD 2013) averted ($645 per LY saved or $511 per
QALY gained). The authors acknowledge that WTP
thresholds levels, and their use, are highly debated in
LMICs. However, it can be regarded as cost-effective if
using the commonly used WHO WTP thresholds of one
to three times the country’s GDP per capita to define a
cost-effective intervention (GDP per capita = $487 in
The Gambia [31]). This was the only published study on
the cost-effectiveness of HBV screening and treatment
performed in a LMIC setting. A strength of this study
includes the use of primary screening data to populate
the model and comprehensive sensitivity analyses on
prevalence, costs and epidemiological parameters.
Testing of ‘high-risk’ groups in HIC
There were six studies that evaluated the cost-effectiveness
of screening and treatment in migrant or refugee popula-
tions in HICs [24–28, 30], and one examined screening all
groups classified as ‘high risk’, in accordance with Italian
guidelines [29].
The study by Wong and colleagues in 2011, looked at
the cost-effectiveness of screening and treatment of im-
migrants for CHB, in Canada [27]. They considered a
screen and treat strategy and a screen, treat or vaccinate
strategy, with status quo (no screening). Screening was
offered by the primary care physician at a visit scheduled
for another reason, described by the authors as a ‘case-
finding’ strategy. They used a hypothetical cohort
(35 year old male) with a baseline HBsAg prevalence
among the immigrant population of 4.81%. Screening
uptake was 100% and it was assumed that 90% of those
eligible would receive treatment. The screen and treat
strategy (with tenofovir) had an ICER of C$69,000/
QALY gained (Canadian$ in 2008). The authors acknow-
ledge the uncertainty around WTP thresholds and de-
scribe this is as likely to be a moderately cost-effective
intervention. The study explores cost-effectiveness by
country of origin, revealing higher cost-effectiveness of a
screen and treat strategy for immigrants born in east
Asia, central and West Africa, corresponding with
higher prevalence rates. A strength of this model is that
it is more clinically representative of HBV than many of
the other models. However, it uses high, and probably
unrealistic, assumptions for uptake of screening.
Another Canadian study by Rossi et al. (2013) [25] looked
at combinations of scenarios involving screening, treatment
and vaccination, among newly arrived immigrants and
refugees. A hypothetical cohort of 250,000 immigrants was
modelled using a societal perspective. The baseline assump-
tions were 70% acceptance of screening, 60% linkage to
care, 75% of those eligible will have treatment and annual
cost of antiviral drugs $8089. The screen and treat scenario
was found to be the most cost-effective with an ICER of
C$40,880/QALY gained (Canadian $ in 2011) and remained
robust over all one way sensitivity analyses. This strategy
exceeds the Canadian WTP threshold adopted in this study
of C$50,000/QALY, when HBsAg prevalence is less than 3%.
An earlier study by Hutton et al. [24] looked at the
cost-effectiveness of screening and vaccination of Asian
Pacific Islander adults for HBV, comparing four strat-
egies of combinations of screen, treatment and vaccin-
ation. They adopted a societal perspective and used a
hypothetical cohort with an average age of 40 years and
a HBsAg prevalence of 10%. The screen and treat strat-
egy was the most cost-effective with an ICER of
$36,000/QALY (USD in 2006) gained (compared to no
screening), even down to an HBsAg prevalence of 1%.
Another, more recent, US study by Jezwa and colleagues
[30], compared the cost-benefits of two overseas pro-
grammes for reducing HBV infection among refugees. They
compared two strategies i. vaccination only and ii. screen-
ing, vaccination and suggested onward treatment on arrival
in USA if HBsAg positive. Their baseline assumptions in-
cluded a HBsAg prevalence of 6.8%, 100% adherence with
screening, 60% of those tested positive for HBsAg linked to
specialist care and 90% adherence to treatment. This was
the only economic evaluation which adopted a cost-benefit
method, where mortality risk reduction benefits were esti-
mated using a value of statistical life approach (VSL). They
found that the screening strategy had a positive net benefit
of $90 million after 5 years, when VSL was estimated at $5
million (USD 2012). A strength of this study was the use of
original data sets of refugee populations in two US states
for the epidemiological data.
The study by Veldhuijzen et al. [28] was the only
European study which looked at the cost-effectiveness of
HBV screening & early treatment of migrants. An active
screening method was used, where the target population
is identified using the municipal population registry and
they receive a postal invitation to attend screening. Their
baseline HBsAg prevalence was 3.35%, with 35% partici-
pation rate in screening, 58% linkage to specialist care
and 75% adherence. Compared to status quo, screening
and treatment had an ICER of €8966/QALY gained and
was therefore reported as cost-effective compared to the
authors’ reported WTP threshold of €20,000/QALY
gained. This study found that despite using low rates of
participation throughout the cascade of care, that
screening is still likely to be cost-effective. A strength of
this study was the inclusion of comprehensive screening
programme costs including personnel costs.
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A study by Rein et al. [26] looked at different methods
of screening for HBV among the Asian migrant popula-
tion in the USA, using actual screening data. This was a
descriptive study with outcome measures given as cost
per person screened and cost per positive case detected.
The screening methods analysed included testing at a
community clinic and other more active community out-
reach models where screening was performed at various
events in the Asian community. The costs per person
screened ranged from $40 to $280 depending on the
method used. Integrating screening into clinical services
was found to be the least costly method, but reached
least people, whereas extending screening outside the
clinical setting was more costly as it included costs of
organising events and volunteer time, but reached more
people. This study provides useful insights into the relative
costs of various screening methods and, unlike some of the
other studies, it includes full costs including those associ-
ated with recruiting patients. However, it does not provide
long term outcomes following on from a positive screening
test and is therefore limited in its generalizability.
Ruggeri et al. [29] looked at screening of all groups
defined as ‘high risk’ (according to local Italian guidelines),
and compared the cost effectiveness of screening followed
by antiviral treatment for CHB. This was compared to the
status quo strategy of no screening, but treatment for
cirrhosis and HCC stages only. A hypothetical cohort of
100,000 individuals was considered and screening and
treatment was found to be cost-effective with an ICER
€18,255/QALY. However, this study included treatment
with suboptimal drug combinations and was based on
unrealistic 100% adherence rates to testing and treatment.
Discussion
Overall, the studies found that testing and treatment for
chronic HBV infection was likely to be cost-effective among
high prevalence groups (such as migrants or refugees) in
HICs and among the general population in a LIC with high
general population seroprevalence. The findings were rela-
tively robust over a wide range of parameters tested. How-
ever, the studies were highly heterogenous in terms of their
settings, model structures, assumptions and willingness-to-
pay thresholds used. This review highlighted the lack of
existing literature on the cost-effectiveness of testing and
treatment in LMICs. The existing literature included only
two previous community-based cost-effectiveness of testing
studies, and further studies of testing among groups classi-
fied as ‘high-risk’ including immigrant populations. Most
studies modelled cost-effectiveness, with only a few estimat-
ing cost-effectiveness directly from clinical studies and
assumed high rates for adherence to the care cascade.
WHO GDG recommendations were formulated based
on consideration of evidence from cost–effectiveness
analyses together with data on HBsAg seroprevalence in
different settings and populations, with considerations of
overall balance of benefits and harms, feasibility and
cost. The caveats of extrapolating cost-effectiveness data
from HICs to LMICs were recognized. Overall, given the
heterogeneity and limited number of studies the
evidence-base used to inform recommendations to the
WHO Clinical Guidelines Committee was rated as low
quality, based on the GRADE system [32]. The WHO
Testing Guidelines recommend general population (con-
ditional recommendation) and ANC testing of pregnant
women (strong recommendation) in settings where the
HBsAg prevalence is >2% and focused testing in popula-
tions classified as high risk in all settings (strong recom-
mendation) [21]. Although general population testing
was estimated to be cost–effective down to prevalence
levels <1%, the GDG proposed a higher threshold of
≥2% to reflect the well accepted thresholds for defining
intermediate (≥2%)/high (≥5%) seroprevalence. It was
recognised that the threshold used by countries will
depend on other country considerations and epidemio-
logical context.
Drivers of cost-effectiveness
Several key drivers of cost-effectiveness were identified
in the review, and are summarized below. Although the
results of the studies performed in HICs are not directly
comparable quantitatively to those performed in LMICs,
in the absence of other literature on testing and treat-
ment for HBV, we have extrapolated and drawn compar-
isons, where appropriate.
Costs
Economic evaluations of testing and treatment for HBV
should ideally include costs of screening, diagnostics,
monitoring and drugs, taking into account, both the cost
of consumables as well as the cost of delivering the
intervention (eg human resources), although the latter is
often captured poorly in studies. The variability in all
these cost components across different settings and over
time, makes comparison of studies difficult. Screening
costs varied between the studies; in the USA the Rein
[33] study reported costs per person screened between
$40 to $280, with the higher costs representing the more
active outreach strategies and in The Gambia,
community-based screening costs were low ($7.43 per
person offered screening). Screening costs were only
found to be drivers of cost-effectiveness in the Wong
[27] and PROLIFICA studies. However, in the Gambia,
the intervention remained below a 3 times GDP per
capita WTP threshold, even if there was a 3-fold in-
crease in screening costs.
A key driver of the cost-effectiveness of a screen and
treat strategy reported in some studies is the cost of the
antiviral drug [22, 24, 25]. The Rossi study used a
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baseline drug cost of $8089/year, to represent the aver-
age cost of tenofovir and entecavir. They varied this
between $7000–$9100/year in their sensitivity analysis
and this changed the ICER by $10,000, while still
remaining below their reported WTP threshold. In the
PROLIFICA study, the generic price of tenofovir ($48)
available for use in HIV programmes in SSA [34] was
used as the base-case. Using the 2014 pharmaceutical
drug price of $207 [35] decreases the cost-effectiveness
of the screening strategy, as it increases the ICER to
$1064/DALY averted.
The cost-effectiveness of screening and treatment
strategies in HIC settings is attributable in part to the
fact that early management reduces the risk of long-
term sequelae, which can incur significant costs (for ex-
ample, estimated costs of managing cirrhosis and HCC
is $9000 and $15,000 per person per year, respectively,
in the Canadian study by Rossi et al. [25]). However, in
LICs, there are currently limited options for manage-
ment of end-stage liver disease (for example, no trans-
plant services, limited endoscopy facilities and limited
palliative care) and patients often die at home, with fam-
ily as primary care-giver. Therefore, more studies are
needed to evaluate whether the costs of the intervention,
from a healthcare perspective, offset the cost avoided of
end stage liver disease. A societal perspective analysis
might be more appropriate for future cost-effectiveness
studies in LMICs. Furthermore, the annual costs of
managing liver disease are variable and largely unknown
and should be the subject of further research [36].
HBsAg prevalence
Although the studies varied in the baseline HBsAg preva-
lence used in the model (2–10%), they reported how the
cost-effectiveness of the intervention would change over a
range of HBsAg prevalence levels. HBsAg prevalence was
found to have a relatively small influence on cost-
effectiveness, over the wide ranges evaluated, in most of
the studies. General population screening was found to
remain cost-effective (ie ICER below the respective WTH
threshold) down to a HBsAg prevalence of 0.3% in the
USA [23] and 1.5% in The Gambia [22]. Screening of
migrants in North America remained cost-effective down
to prevalence levels of 1% [24] - 3% [37]. An important
caveat is that there is inter-study variation as to how ‘cost-
effectiveness’ is assessed; each using differing scales of cost
and WTP thresholds - concepts that are also debated [38].
Therefore extrapolation of the HIC results to LMIC is
difficult, and the absolute threshold cut-off for HBsAg
prevalence cannot be guided based on the existing litera-
ture alone. However, there is concordance between studies
of cost-effectiveness of such a strategy even at low HBsAg
prevalence levels. This has important implications for
choice of testing approach when considering testing in
other countries with different prevalence profiles and
different levels of historical vaccination coverage.
Patient Behaviours
Adherence to treatment and linkage to care were
reported as key drivers of cost-effectiveness in some of
the studies [25, 28]. Veldhuijzen et al. reported that vari-
ation in rates of linkage to care and treatment adherence
had the largest influence on ICER (ICER varied by about
€3000 over the ranges tested, 39–75%, 50–100%, for
linkage and adherence, respectively). In contrast, in The
Gambia, these factors were less influential on the cost-
effectiveness. Uptake of screening is not reported to be a
key driver of ICER in the studies.
Disease progression rates
Although the HBV economic evaluations varied in their
natural history models and baseline parameter assump-
tions, most showed that the cost-effectiveness was rela-
tively sensitive to variations in disease progression rates.
The Dutch study [28], showed that varying parameters
between a range representing fast disease to slower dis-
ease progression, showed significant variation in ICER
between €5000 and €60,000/QALY gained, respectively,
a trend which was also seen in other studies [24, 27].
The Eckman study showed that the ICER was most sen-
sitive to the rate of spontaneous HBeAg seroconversion
assumed to be 5% at baseline, but exceeded the WTP
threshold if increased to 10%. The study in The Gambia
also showed that many of the transition rates, were
influential on ICER [22]. However, given the complex
and heterogenous natural history of HBV, both within
and between populations, and lack of natural history
progression rate data specific to all populations, this is
likely to remain a limitation of all HBV models.
Effectiveness of antiviral therapy
Effectiveness of antiviral therapy was found to be influ-
ential on ICER in some studies [24, 27], but not in
others [22]. This discrepancy is likely to be due to study
differences on the type of antiviral drug used and effi-
cacy assumptions (some of which have been superseded
with more current data). For example, the older studies
often included low-barrier to resistance drugs like lami-
vudine or interferon, whilst the newer studies mainly
used tenofovir or entecavir. Therefore, conclusions as to
the influence of these parameters on the result, as well
as comparisons between studies have to be interpreted
with caution.
Other factors
The assumptions which underlie the methodological ap-
proach taken will also affect the conclusion of cost-
effectiveness studies, for example, health utility values
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used for Quality Adjusted Life Year (QALY) assumptions
[23, 27] discount rate [27, 30] and the cost-effectiveness
thresholds used [39]. Although guidelines exist as refer-
ence for the techniques used, the variability between stud-
ies limits accurate comparisons. A full discussion of these
factors is outside the scope of this current manuscript.
Generalisability of results
There are several key challenges in the use of these cost-
effectiveness studies to inform WHO recommendations
on testing approaches. WHO recommendations are pri-
marily to guide strategy decisions in LMICs, but the lit-
erature for HBV in these countries is sparse. Direct
comparison of results from cost-effectiveness analyses
between countries or regions with such differing health
care structures, costs, patient behaviors, disease preva-
lence profiles and willingness-to-pay thresholds can be
misleading and needs to be interpreted with caution.
However, funding, timescales and resources are unlikely
to be available for individual country-level analyses to be
a realistic goal across disease areas, before a new testing
strategy is implemented. Therefore, some cautious infer-
ence can be drawn from existing literature. Other limita-
tions of this review include the fact that the search was
only conducted in Pubmed and limited to English lan-
guage articles only, therefore excluding further poten-
tially relevant studies particularly from LMICs. The
heterogeneity in methods, settings and assumptions used
between models also limit the quantitative synthesis of
study results.
Considerations regarding where to test
Careful consideration needs to be given regarding alter-
native places to increase testing opportunities for HBV
infection, whilst ensuring linkage to care for treatment.
Community-level testing may be considered the most
active type of case-finding approach with outreach com-
ponents and therefore likely the most labour and
resource intensive. However, within PROLIFICA, it was
found to be cost-effective, with low testing costs of $7.43
per person offered testing. Various examples of commu-
nity outreach programmes exist in the field of HIV [40],
and comparable strategies could be considered for HBV,
with the caveat that ‘high risk’ groups will not be as ap-
plicable to HBV infection. However, a strategy of active
door-to-door testing may not be a feasible in all settings.
The use of media campaigns to sensitise and educate the
population about the benefits of early testing for HBV
could be an alternative method to increase testing, and
there is a need for further implementation research to
evaluated the impact of such campaigns in LMICs.
Health-care facility testing includes primary care, in-
patient and outpatient settings or specialist clinics (eg
HIV or STD clinics), and can be used for both routine
general population testing approaches as well as those
with a clinical indication for testing (eg abnormal liver
function tests, abnormal ultrasound scan, family history
of liver disease or other clinical suspicion of liver
disease). A clinically guided testing approach is likely to
reveal a higher proportion of people with HBV in highly
endemic settings and could be cheaper, but would be
limited in its reach and ability to pick up early asymp-
tomatic infection, and would need to take into account
the mortality of the sub-population seeking healthcare.
The screening of pregnant women for HBsAg (with or
without HBeAg testing) in antenatal care (ANC) settings
has been considered in previous cost-effectiveness ana-
lyses, as was not a focus of this current narrative review.
A limitation of these previous studies was that they only
considered the reduction in MTCT and benefits to the
child. None considered onward linkage into care or
treatment for the mother, to reduce their risk of progres-
sion of liver disease. Furthermore, many were older
studies published before 2000 (summarised in a review
by Hahne et al. [17]) and were performed mainly in
HICs. Cost-effectiveness analyses in this setting needs to
balance the lower incremental costs of HBV testing dur-
ing an already planned ANC visit, with the lower HBsAg
prevalence and slower rates of progression to HCC
among women. However, since testing of mothers for
HBV has benefits to both the mother and child, this is
likely to be cost-effective. Since there is variable percent-
age of attendance to antenatal care depending on geo-
graphic region [41] this approach should also consider
factors which will help strengthen ANC coverage overall,
including increasing patient education.
Blood donor screening for HBV already forms part of
WHO recommendations in order to prevent transmission
of blood-borne viruses to the recipient [42]. However, in
LMICs, this is rarely accompanied by the HBsAg positive
donor being informed of this positive result, counselled
and linked into care for clinical evaluation and treatment
[43]. As part of the PROLIFICA study in The Gambia,
blood donors who had tested HBsAg positive at the blood
bank were linked into care and offered antiviral therapy
[5]. The cohort of blood donors, compared to those who
were screened in the community, had a higher proportion
who tested HBsAg positive, majority males, younger ages,
a higher proportion requiring treatment and a lower pro-
portion who linked to care. However, as blood donors
form only a small fraction of the population, this approach
is likely to be limited in its reach and population level ef-
fectiveness and probably should be seen as a complemen-
tary, rather than alternative to a wider screening strategy.
Although other methods of testing are used, to varying
levels, worldwide, including testing in work places, test-
ing of healthcare workers, couples pre-marriage, military
recruits or pre-employment screening, implementation
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and guidance of these methods are highly heterogenous
between countries [48] and are not accompanied by
effectiveness or cost-effectiveness data. Care must also
be taken to avoid testing methods which are associated
with stigma or discrimination.
Conclusions
This review has highlighted the paucity of data on the cost-
effectiveness of testing and treatment for HBV infection,
especially in LMICs. However, although it was not possible
to formulate strong recommendations regarding the best
testing approach, based on cost-effectiveness data alone,
overall our narrative review of available studies suggests that
offering testing to the general population with subsequent
antiviral treatment is cost-effective in HICs [23], as well as
LICs [22], even when the prevalence is low. Furthermore,
testing also has benefits, which extend beyond the person
tested, for example prevention-of-mother to child transmis-
sion. Ultimately, each country must determine its optimal
testing approach based on local epidemiology, healthcare in-
frastructure and resources. The 2017 WHO testing guide-
lines includes a strategic framework to guide countries’
decision-making on selecting testing approaches. The WHO
guidelines recommend that testing approaches in the general
population and focussed testing in most affected/higher-risk
populations should make use of existing community-based
or health facility testing opportunities or programmes such
as at antenatal, HIV or TB clinics. A further emphasis was
on ensuring linkage to prevention, care and treatment ser-
vices following testing.
Further large-scale operational research is urgently
needed in other high-endemic, low-income settings. Fur-
thermore, in addition to cost-effectiveness analyses, eco-
nomic evaluations that examine the affordability and
budgetary impact of scaling up testing and treatment in-
terventions for HBV would be helpful in policy planning.
Improving country access to generic priced tenfovir for
HBV mono-infection in all LMICs is also vital to allow-
ing adoption of affordable widescale HBV treatment pro-
grammes, which is still not the case in most of SSA,
outside the remit of the HIV programme. Furthermore,
HBV screening costs could be shared across other dis-
ease programmes, as there are overlapping benefits and
synergies with maternal and child health goals and HIV
infrastructure and experience.
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